SCHEMBL1278342

SCHEMBL1278342

CC(C)[Si](OC(=O)C(F)(F)F)(C(C)C)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6514729 0.80 PRKCA (0.33)
SCHEMBL5016853 0.77
SCHEMBL31042731 0.74
SCHEMBL22557953 0.73 TSHR (0.32)
SCHEMBL321296 0.72 TSHR (0.33)
SCHEMBL1050079 0.72
SCHEMBL423208 0.72
SCHEMBL4265048 0.72
SCHEMBL329028 0.71 CA2 (0.36)
SCHEMBL28601036 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114874292-A Multi-target chimeric peptide compound, preparation method and application thereof 南通大学 2022-08-09 CN claimed
CN-116640100-A Solid-phase synthesis method of fluororalrana 河北圣雪大成制药有限责任公司 2023-08-25 CN disclosed
CN-109153703-B Immunomodulator 百时美施贵宝公司 2022-09-23 CN disclosed
CN-114874292-A Multi-target chimeric peptide compound, preparation method and application thereof 南通大学 2022-08-09 CN disclosed
CN-107223129-B Immunomodulator 百时美施贵宝公司 2022-01-04 CN disclosed
CN-107207568-B Immunomodulator 百时美施贵宝公司 2021-12-10 CN disclosed
CN-106999536-B Macrocyclic inhibitors of PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions 百时美施贵宝公司 2020-11-27 CN disclosed
CN-111051332-A Immunomodulator 百时美施贵宝公司 2020-04-21 CN disclosed
EP-3099694-A1 COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2016-12-07 EP disclosed
WO-2015113451-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-08-06 WO disclosed
US-7498337-B2 Acid secretion inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-03-03 US disclosed
CN-101300229-A 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors TAKEDA PHARMACEUTICAL (JP) 2008-11-05 CN disclosed
EP-1919865-A1 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2008-05-14 EP disclosed
US-20070060623-A1 antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-15 US disclosed
WO-2007026916-A1 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed
EP-1027370-A2 A METHOD FOR MAPPING THE ACTIVE SITES BOUND BY ENZYMES THAT COVALENTLY MODIFY SUBSTRATE MOLECULES PEPTIDE THERAPEUTICS LIMITED (GB) 2000-08-16 EP disclosed
WO-1999023109-A2 A METHOD FOR MAPPING THE ACTIVE SITES BOUND BY ENZYMES THAT COVALENTLY MODIFY SUBSTRATE MOLECULES PEPTIDE THERAPEUTICS LIMITED (GB) 1999-05-14 WO disclosed
CN-1088211-A Two indoles and compound SCHERING CORP (US) 1994-06-22 CN disclosed
CN-1024626-C Tetrahydrobenz [c,d] indole serotonin agonists LILLY CO ELI (US) 1994-05-25 CN disclosed
CN-1046330-A Tetrahydro benzo [c, d] indole serotonin stimulant LILLY CO ELI (US) 1990-10-24 CN disclosed